Literature DB >> 35004963

Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: far from a clinical consensus.

Wei-Feng Qu1, Wei-Ren Liu1, Ying-Hong Shi1.   

Abstract

Entities:  

Year:  2021        PMID： 35004963      PMCID： PMC8683926          DOI： 10.21037/hbsn-21-362

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  15 in total

1.  A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.

Authors:  Richard D Kim; Vincent Chung; Olatunji B Alese; Bassell F El-Rayes; Daneng Li; Taymeyah E Al-Toubah; Michael J Schell; Jun-Min Zhou; Amit Mahipal; Baek Hui Kim; Dae Won Kim
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

2.  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

Authors:  John N Primrose; Richard P Fox; Daniel H Palmer; Hassan Z Malik; Raj Prasad; Darius Mirza; Alan Anthony; Pippa Corrie; Stephen Falk; Meg Finch-Jones; Harpreet Wasan; Paul Ross; Lucy Wall; Jonathan Wadsley; Jeff T R Evans; Deborah Stocken; Raaj Praseedom; Yuk Ting Ma; Brian Davidson; John P Neoptolemos; Tim Iveson; James Raftery; Shihua Zhu; David Cunningham; O James Garden; Clive Stubbs; Juan W Valle; John Bridgewater
Journal:  Lancet Oncol       Date:  2019-03-25       Impact factor: 41.316

3.  Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.

Authors:  Oliver Klein; Damien Kee; Adnan Nagrial; Ben Markman; Craig Underhill; Michael Michael; Louise Jackett; Caroline Lum; Andreas Behren; Jodie Palmer; Niall C Tebbutt; Matteo S Carlino; Jonathan Cebon
Journal:  JAMA Oncol       Date:  2020-09-01       Impact factor: 31.777

4.  Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy.

Authors:  Meng-Xin Tian; Yu-Fu Zhou; Wei-Feng Qu; Wei-Ren Liu; Lei Jin; Xi-Fei Jiang; Han Wang; Chen-Yang Tao; Pei-Yun Zhou; Yuan Fang; Zhen-Bin Ding; Yuan-Fei Peng; Jian Zhou; Jia Fan; Ying-Hong Shi
Journal:  Cancer Immunol Immunother       Date:  2019-07-23       Impact factor: 6.968

5.  Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma.

Authors:  John T Miura; Fabian M Johnston; Susan Tsai; Ben George; Jim Thomas; Dan Eastwood; Anjishnu Banerjee; Kathleen K Christians; Kiran K Turaga; Timothy M Pawlik; T Clark Gamblin
Journal:  Ann Surg Oncol       Date:  2015-03-17       Impact factor: 5.344

6.  Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?

Authors:  Ariella M Altman; Scott Kizy; Schelomo Marmor; Jane Y C Hui; Todd M Tuttle; Eric H Jensen; Jason W Denbo
Journal:  Hepatobiliary Surg Nutr       Date:  2020-10       Impact factor: 7.293

7.  Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Authors:  Julien Edeline; Meher Benabdelghani; Aurélie Bertaut; Jérôme Watelet; Pascal Hammel; Jean-Paul Joly; Karim Boudjema; Laetitia Fartoux; Karine Bouhier-Leporrier; Jean-Louis Jouve; Roger Faroux; Véronique Guerin-Meyer; Jean-Emmanuel Kurtz; Eric Assénat; Jean-François Seitz; Isabelle Baumgaertner; David Tougeron; Christelle de la Fouchardière; Catherine Lombard-Bohas; Eveline Boucher; Trevor Stanbury; Christophe Louvet; David Malka; Jean-Marc Phelip
Journal:  J Clin Oncol       Date:  2019-02-01       Impact factor: 44.544

8.  Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis.

Authors:  Xu-Feng Zhang; Feng Xue; Ding-Hui Dong; Matthew Weiss; Irinel Popescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; Bas Groot Koerkamp; Endo Itaru; Yi Lv; Timothy M Pawlik
Journal:  Ann Surg       Date:  2021-12-01       Impact factor: 12.969

Review 9.  Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.

Authors:  Alphonse E Sirica; Gregory J Gores; John D Groopman; Florin M Selaru; Mario Strazzabosco; Xin Wei Wang; Andrew X Zhu
Journal:  Hepatology       Date:  2019-03-25       Impact factor: 17.298

Review 10.  Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.

Authors:  Yun Shin Chun; Milind Javle
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302
View more
  1 in total

1.  Exploring the function of stromal cells in cholangiocarcinoma by three-dimensional bioprinting immune microenvironment model.

Authors:  Changcan Li; Bao Jin; Hang Sun; Yunchao Wang; Haitao Zhao; Xinting Sang; Huayu Yang; Yilei Mao
Journal:  Front Immunol       Date:  2022-08-02       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.